Nuance Pharma Announces Dosing of First Patient in ENHANCE - China Phase III Trial for Chronic Obstructive Pulmonary Disease ("COPD")
- Written by PR Newswire
SHANGHAI, April 7, 2023 /PRNewswire/ -- Nuance Pharma ("the Company") announces dosing of first patient in the ENHANCE - China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease ("COPD") of its novel solution Ensifentrine in mainland China.
Ensifentrine is a first-in-class, selective, dual inhibitor of the...
